Lantus Versus Levemir Treat-To-Target (L2T3)

September 14, 2009 updated by: Sanofi

Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir.

Primary objective:

To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c < 7% at the end of the treatment period and do not experience symptomatic hypoglycemia, confirmed by plasma glucose (PG) ≤ 56 mg/dL (3.1 mmol/L)

Secondary objectives:

  • To compare between the 2 treatment groups, the percentage of patients who reach the target of HbA1c < 7% and < 6.5% at the end of the treatment period
  • To compare the changes in HbA1c and fasting plasma glucose (FPG)
  • To compare the evolution of blood glucose profiles
  • To compare the day to day FPG variability, the insulin doses
  • To determine in each treatment group the biochemical and patient-related determinants of failure to reach HbA1c targets
  • To compare the overall incidence and rate of symptomatic hypoglycemia and nocturnal symptomatic hypoglycemia confirmed by PG ≤ 56 mg/dL (3.1 mmol/L)
  • To compare over the treatment period, the overall incidence and rate of symptomatic hypoglycemia and symptomatic nocturnal hypoglycemia (with PG ≤ 70 mg/dL [3.9 mmol/L]), of symptomatic day-time hypoglycemia (with PG ≤ 70 mg/dL and with PG ≤ 56 mg/dL), of severe hypoglycemia, of asymptomatic hypoglycemia with PG ≤ 56 mg/dL
  • To compare the overall safety: incidence of adverse events (including serious hypoglycemia and local tolerance at injection site), change in body weight, in waist circumference and in waist / hip ratio
  • To assess the quality of life and treatment satisfaction

Study Overview

Status

Completed

Study Type

Interventional

Enrollment (Actual)

973

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • North Ryde, Australia
        • Sanofi-Aventis
      • Sao Paolo, Brazil
        • Sanofi-Aventis
      • Laval, Canada
        • Sanofi-Aventis
      • Hoersholm, Denmark
        • Sanofi-Aventis
      • Helsinki, Finland
        • Sanofi-Aventis
      • Berlin, Germany
        • Sanofi-Aventis
      • Mumbai, India
        • Sanofi-Aventis
      • Dublin, Ireland
        • Sanofi-Aventis
      • Seoul, Korea, Republic of
        • Sanofi-Aventis
      • Gouda, Netherlands
        • Sanofi-Aventis
      • Porto Salvo, Portugal
        • Sanofi-Aventis
      • Bucharest, Romania
        • Sanofi-Aventis
      • Moscow, Russian Federation
        • Sanofi-Aventis
      • Belgrade, Serbia
        • Sanofi-Aventis
      • Barcelona, Spain
        • Sanofi-Aventis
      • Stockholm, Sweden
        • Sanofi-Aventis
      • Meyrin, Switzerland
        • Sanofi-Aventis
      • Taipe, Taiwan
        • Sanofi-Aventis
      • Istanbul, Turkey
        • Sanofi-Aventis
      • Guildford, United Kingdom
        • Sanofi-Aventis

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Type 2 diabetes for at least 1 year
  • Insulin naïve
  • Treated with stable doses of oral antidiabetics for at least 3 months prior to study start, including at least metformin (at least 1g/day)
  • 7% ≤ HbA1c ≤ 10.5 %
  • Body mass index (BMI) < 40 kg/m²
  • Ability and willingness to perform blood glucose monitoring using a blood glucose meter and to use a patient diary

Exclusion Criteria:

  • Type 1 diabetes
  • Current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for less than 1 week)
  • Treatment with glucagon-like peptide (GLP)-1 receptor agonists or with dipeptidyl peptidase (DPP)-IV inhibitors
  • Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)
  • Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method)
  • Breast-feeding
  • History of hypersensitivity to the study drugs or to drugs with a similar chemical structure
  • Treatment with systemic corticosteroids in the 3 months prior to study entry
  • Treatment with any investigational product in the 2 months prior to study entry
  • Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
  • Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult
  • Impaired hepatic function as shown by Alamine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal range at study entry
  • Impaired renal function as shown by serum creatinine ≥ 1.5 mg/dL (≥ 133 μmol/L) in men and ≥ 1.4 mg/dL (124 μmol/L) in women at study entry
  • History of drug or alcohol abuse in the last year

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
Insulin Glargine
Subcutaneous injection, once a day in the evening
Active Comparator: 2
Insulin Detemir
Subcutaneous injection, twice a day at breakfast and before dinner

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
HbA1c recorded
Time Frame: At baseline, week 12 and week 24
At baseline, week 12 and week 24
Self-monitored fasting BG in both treatment arms and pre-dinner BG in detemir arm
Time Frame: On the 4 consecutive days before each visit
On the 4 consecutive days before each visit
Self-monitored BG values from 8-point 24-hour profile recorded on 2 consecutive days
Time Frame: Within the week prior to baseline, week 12 and week 24
Within the week prior to baseline, week 12 and week 24
Episodes of hypoglycemia (symptomatic, total and categorized as day-time/nocturnal, severe or asymptomatic)
Time Frame: All across the study
All across the study
Self-monitored BG values whenever patient experiences symptoms possibly related to hypoglycemia.
Time Frame: All across the study
All across the study

Secondary Outcome Measures

Outcome Measure
Time Frame
Doses of insulin glargine or insulin detemir
Time Frame: Daily
Daily
Laboratory fasting plasma glucose
Time Frame: At baseline, week 12 and week 24
At baseline, week 12 and week 24
Insulinemia and fasting C-peptide level
Time Frame: At baseline
At baseline
Lipid profile
Time Frame: at baseline and week 24
at baseline and week 24
Patient reported outcomes (quality of life and treatment satisfaction)
Time Frame: at baseline, week 4, week 12 and at the last visit
at baseline, week 4, week 12 and at the last visit
Safety data: occurrence of adverse events and weight
Time Frame: assessed at each visit
assessed at each visit
Waist and hip circumferences
Time Frame: measured at baseline, week 12 and week 24
measured at baseline, week 12 and week 24
Systolic and diastolic blood pressure
Time Frame: measured at study entry, baseline, week 12 and week 24
measured at study entry, baseline, week 12 and week 24
Physical examination
Time Frame: performed at study entry and at last visit.
performed at study entry and at last visit.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Valérie Pilorget, Sanofi

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2006

Primary Completion (Actual)

June 1, 2008

Study Registration Dates

First Submitted

November 29, 2006

First Submitted That Met QC Criteria

November 29, 2006

First Posted (Estimate)

November 30, 2006

Study Record Updates

Last Update Posted (Estimate)

September 15, 2009

Last Update Submitted That Met QC Criteria

September 14, 2009

Last Verified

September 1, 2009

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe